Építés alatt – nem éles oldal
Belépés
Résztvevőt keres3. fázis

A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).

A legfontosabb adatok

Ki végzi
Kardigan Inc.
Hol
Amsterdam, Maastricht és Rotterdam (Hollandia)Mind a 3 helyszín megnézéseMég 8 másik országban, 36 helyszínen
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
211 fő, tervezett
Kezdés
2026. okt. 15.
Várható befejezés
2032. nov. 6.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. november 6.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with symptomatic genetic and familial dilated cardiomyopathy who completed the DAN-301 study. It looks at the long-term safety of danicamtiv.

Életkor
18 years and older.
Nem
All sexes can join.
A betegség stádiuma
Symptomatic genetic and familial dilated cardiomyopathy, a weakened and enlarged heart muscle that runs in families.
Korábbi kezelés
People must have completed 24 weeks of blinded study treatment (the Week 26 Visit) and planned assessments in Part 1 or Part 2 of the DAN-301 study.

A részvétel fő kizáró okai

  • Heart attack-type event, heart artery procedure, stroke, or hospital stay or IV diuretic for worse heart failure in the last 90 days.
  • Has a heart pump (ventricular assist device), or a heart pump, heart transplant, CRT or major surgery planned in the next 6 months.
  • Active liver disease, severe kidney problems, or cancer needing treatment after joining DAN-301 that could shorten life.
  • Life expectancy less than 6 months.
  • Pregnant or breastfeeding.

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Is an adult ≥18 years of age at the Screening visit
  • Participants must have completed 24 weeks of blinded study treatment (corresponding to the Week 26 Visit in DAN-301) and planned assessments in Part 1 or Part 2 of the DAN-301 study
  • Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. All participants, if sexually active, must use a highly effective birth control methods listed in the protocol from the Screening visit through 3 months after the last dose of Investigational Medicinal Product
  • Is able to understand and comply with the study procedures, understand the risks involved in the study, and provide written informed consent according to local and institutional guidelines before the first study-specific procedure

Ki nem vehet részt

  • Participated in a clinical trial (excluding DAN-301 study) in which the participant received any investigational drug (or is currently using an investigational device) within 30 days prior to enrollment, or less than 5 times the respective elimination half-life (whichever is longer)
  • Participant is on prohibited medication at the time of enrollment
  • Recent (<90 days) acute coronary syndrome or hemodynamically significant epicardial coronary disease or coronary revascularization
  • Has active liver disease
  • Has hypersensitivity to danicamtiv or any of the components of the danicamtiv formulation
  • Recent (<90 days) hospitalization for worsening heart failure (HF) or use of intravenous (IV) diuretic
  • Hospitalization for sepsis or other systemic infections within 30 days of Screening
  • Any malignancy requiring treatment after enrollment in DAN-301 that could limit patient’s survival
  • Severe renal insufficiency
  • History or evidence of any clinically significant disorder, condition, or disease
  • Anticipated heart transplantation in the next 6 months
  • Has planned cardiac resynchronization therapy (CRT) or major surgery in the next 6 months
  • Serum potassium at levels identified in the protocol
  • Any persistent (2 or more) out-of-range, clinically significant safety laboratory parameters based on Central Laboratory results at enrollment
  • Hemoglobin at levels identified in the protocol
  • Serum creatine kinase at levels identified in the protocol
  • Has a ventricular assist device or ventricular assist device placement planned in the next 6 months
  • Thyroid-stimulating hormone at levels identified in the protocol
  • Has life expectancy less than 6 months
  • Is pregnant or breastfeeding
  • Is employed by or is a first-degree relative of someone employed by the Sponsor, the Investigator, or his/her staff or family
  • Other recent (<90 days) cardiovascular events (e.g., cerebrovascular accident)

Helyszínek itt: Hollandia

Még 8 másik országban, 36 helyszínen

  • Amsterdam UMC StichtingAmsterdam, HollandiaToborzás még nem indult
  • Academisch Ziekenhuis MaastrichtMaastricht, HollandiaToborzás még nem indult
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, HollandiaToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

To assess the long-term safety and tolerability of danicamtiv in participants with symptomatic genetic and familial Dilated Cardiomyopathy (DCM).

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. november 6.